Sitaxentan

Drug Profile

Sitaxentan

Alternative Names: IPI 1040; PF-1228305; Sitaxsentan; Sitaxsentan sodium; TBC 11251; Thelin

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Encysive Pharmaceuticals
  • Developer Pfizer
  • Class Antihypertensives; Benzodioxoles; Heart failure therapies; Isoxazoles; Small molecules; Sulfonamides; Thiophenes
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension

Highest Development Phases

  • Market Withdrawal Pulmonary arterial hypertension
  • Discontinued Heart failure; Kidney disorders

Most Recent Events

  • 10 Dec 2010 Discontinued - Phase-II for Kidney disorders in United Kingdom (PO)
  • 10 Dec 2010 Discontinued - Phase-III for Pulmonary hypertension in Japan (PO)
  • 10 Dec 2010 Discontinued - Phase-III for Pulmonary hypertension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top